Sanofi/MACK Candidate Progresses - Analyst Blog


Merrimack Pharmaceuticals, Inc. ( MACK ) recently announced that it has completed the enrollment process for a phase II trial on its oncology candidate, MM-121. The phase II trial is designed to evaluate the efficacy of MM-121 in combination with Bristol-Myers Squibb 's ( BMY ) Taxol (paclitaxel) in advanced ovarian cancer patients who are platinum-resistant or platinum refractory. Merrimack is collaborating with Sanofi ( SNY ) for MM-121.

The open-label, randomized phase II trial is designed to evaluate the efficacy of MM-121 in combination with Taxol versus Taxol alone in 223 patients enrolled in the US and Europe. The primary endpoint of the trial is progression-free survival (PFS). Merrimack expects that top-line data from the phase II trial will be released in the second half of 2013.

MM-121 is also being evaluated for other oncology indications including hormone sensitive breast cancer, non-small cell lung cancer (NSCLC) and HER2 negative neoadjuvant breast cancer.

We note that Merrimack and Sanofi inked an exclusive global licensing agreement in Oct 2009 for the development and co-commercialization of MM-121. Under the terms of the agreement, for each indication, Merrimack will be responsible for the development of MM-121 till phase II proof-of-concept. Thereafter Sanofi will take up development and commercialization activities. Merrimack has the right to co-promote MM-121in the US, following its approval.

Sanofi carries a Zacks Rank #3 (Hold) in the short run, while Merrimack carries a Zacks Rank #4 (Sell). Right now, Novo Nordisk ( NVO ) looks more attractive in the pharma space with a Zacks Rank #2 (Buy).

BRISTOL-MYERS (BMY): Free Stock Analysis Report

MERRIMACK PHAR (MACK): Free Stock Analysis Report

NOVO-NORDISK AS (NVO): Free Stock Analysis Report

SANOFI-AVENTIS (SNY): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

This article appears in: Investing , Business , Stocks

Referenced Stocks: BMY , MACK , NVO , PFS , SNY

More from

Related Videos



Most Active by Volume

  • $10.59 ▲ 13.26%
  • $16.27 ▲ 1.12%
  • $103.30 ▲ 0.78%
  • $20.65 ▲ 5.52%
  • $12.63 ▲ 8.13%
  • $76.68 ▲ 2.49%
  • $34.57 ▼ 1.00%
  • $3.64 ▲ 0.28%
As of 9/2/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by